Literature DB >> 18981762

Optimal use of maraviroc in clinical practice.

Vincent Soriano, Anna María Geretti, Carlo-Federico Perno, Gerd Fätkenheuer, Deenan Pillay, Jacques Reynes, Giuseppe Tambussi, Vincent Calvez, José Alcamí, Juergen Rockstroh.   

Abstract

Mesh：

Substances：

Year:  2008        PMID： 18981762     DOI： 10.1097/QAD.0b013e3283136d95

Source DB:  PubMed          Journal:  AIDS        ISSN： 0269-9370            Impact factor:   4.177


× No keyword cloud information.
  9 in total

1.  Deep sequencing to infer HIV-1 co-receptor usage: application to three clinical trials of maraviroc in treatment-experienced patients.

Authors:  Luke C Swenson; Theresa Mo; Winnie W Y Dong; Xiaoyin Zhong; Conan K Woods; Mark A Jensen; Alexander Thielen; Douglass Chapman; Marilyn Lewis; Ian James; Jayvant Heera; Hernan Valdez; P Richard Harrigan
Journal:  J Infect Dis       Date:  2011-01-15       Impact factor: 5.226

2.  Inhibition of envelope-mediated CD4+-T-cell depletion by human immunodeficiency virus attachment inhibitors.

Authors:  Louis Alexander; Sharon Zhang; Brian McAuliffe; David Connors; Nannon Zhou; Tao Wang; Michele Agler; John Kadow; Pin-Fang Lin
Journal:  Antimicrob Agents Chemother       Date:  2009-08-31       Impact factor: 5.191

3.  In vitro effect of anti-human immunodeficiency virus CCR5 antagonist maraviroc on chemotactic activity of monocytes, macrophages and dendritic cells.

Authors:  R Rossi; M Lichtner; A De Rosa; I Sauzullo; F Mengoni; A P Massetti; C M Mastroianni; V Vullo
Journal:  Clin Exp Immunol       Date:  2011-11       Impact factor: 4.330

Review 4.  Prevalence of drug interactions in hospital healthcare.

Authors:  María Espinosa-Bosch; Bernardo Santos-Ramos; María Victoria Gil-Navarro; María Dolores Santos-Rubio; Roberto Marín-Gil; Paloma Villacorta-Linaza
Journal:  Int J Clin Pharm       Date:  2012-09-11

5.  Pharmacotherapy of HIV-1 Infection: Focus on CCR5 Antagonist Maraviroc.

Authors:  Olga Latinovic; Janaki Kuruppu; Charles Davis; Nhut Le; Alonso Heredia
Journal:  Clin Med Ther       Date:  2009

Review 6.  Virus maturation as a new HIV-1 therapeutic target.

Authors:  Catherine S Adamson; Karl Salzwedel; Eric O Freed
Journal:  Expert Opin Ther Targets       Date:  2009-08       Impact factor: 6.902

7.  In vitro downregulation of matrix metalloproteinase-9 in rat glial cells by CCR5 antagonist maraviroc: therapeutic implication for HIV brain infection.

Authors:  Pasqua Gramegna; Tiziana Latronico; Maria Teresa Branà; Gaetano Di Bari; Fabio Mengoni; Valeria Belvisi; Maria T Mascellino; Miriam Lichtner; Vincenzo Vullo; Claudio M Mastroianni; Grazia M Liuzzi
Journal:  PLoS One       Date:  2011-12-08       Impact factor: 3.240

8.  Chemokine co-receptor usage in HIV-1-infected treatment-naïve voluntary counselling and testing clients in Southern Taiwan.

Authors:  Hung-Chin Tsai; Pei-Yun Chou; Shue-Ren Wann; Susan Shin-Jung Lee; Yao-Shen Chen
Journal:  BMJ Open       Date:  2015-04-29       Impact factor: 2.692

9.  Anti-α4 Integrin Antibody Blocks Monocyte/Macrophage Traffic to the Heart and Decreases Cardiac Pathology in a SIV Infection Model of AIDS.

Authors:  Joshua A Walker; Graham A Beck; Jennifer H Campbell; Andrew D Miller; Tricia H Burdo; Kenneth C Williams
Journal:  J Am Heart Assoc       Date:  2015-07-16       Impact factor: 5.501
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.